Lulipoint Cream contains Luliconazole 1.0% w/w, a topical antifungal agent belonging to the imidazole class, indicated for the treatment of superficial fungal infections of the skin. Luliconazole exhibits broad-spectrum antifungal activity against dermatophytes, yeasts, and molds by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. This cream is primarily used in the management of conditions such as tinea corporis, tinea cruris, tinea pedis, and candidal infections of the skin. Lulipoint Cream is applied topically once daily to the affected area and surrounding skin after cleansing and drying, typically for a duration of 2 to 4 weeks depending on the severity and type of infection. The formulation is well-tolerated with minimal local adverse effects, which may include mild burning, itching, or erythema at the application site. It is contraindicated in patients with known hypersensitivity to Luliconazole or any component of the cream. Caution is advised when used in pregnant or lactating women, and systemic absorption is minimal, reducing the risk of systemic side effects. Lulipoint Cream offers an effective and convenient option for the topical management of fungal dermatoses.